Device-Drug Combination

Device-drug combinations integrate pharmaceutical active ingredients within medical devices including inhalers, transdermal patches, injectors, and implantable systems requiring synergistic evaluation of drug and device components. Regulatory pathways vary internationally with some jurisdictions applying pharmaceutical frameworks and others employing device-specific requirements. Device functionality critically influences drug bioavailability and therapeutic efficacy, necessitating comprehensive interaction assessment. Manufacturing compatibility ensures device materials withstand drug exposure without leaching or altering pharmaceutical stability.

Quality specifications address both pharmaceutical and device attributes including aerosol particle size distribution, injection accuracy, and transdermal permeation rates. Non-clinical testing evaluates device performance across temperature ranges, humidity conditions, and storage durations. Clinical trials assess usability with diverse patient populations including those with reduced dexterity or visual impairments. Post-approval monitoring addresses device malfunctions that compromise drug delivery and patient safety. Regulatory submissions require integrated quality strategies addressing interdependent device-drug interactions ensuring safe and effective performance.